Pharmacokinetics and safety propiverine in patients with fatty liver disease

European Journal of Clinical Pharmacology

Volumn 54, Issue 9-10, 1998, Pages 767-771

  Siepmann, M ^a   Nokhodian, A ^b   Thummler D ^c   Kirch, W ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b Rehabilitation Clinic   (Germany)

^c APOGEPHA Arzneimittel GmbH   (Germany)

Author keywords

Adverse effects; Fatty liver disease; Pharmacokinetics; Propiverine

Indexed keywords

PROPIVERINE;

ADULT; AGED; ANTICHOLINERGIC EFFECT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; DOSE TIME EFFECT RELATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG HALF LIFE; FATTY LIVER; FEMALE; FIRST PASS EFFECT; HUMAN; LIVER FUNCTION; MALE; PRIORITY JOURNAL; VISUAL IMPAIRMENT; XEROSTOMIA;

ADULT; AGED; AREA UNDER CURVE; BENZILATES; BIOTRANSFORMATION; FATTY LIVER; FEMALE; HALF-LIFE; HUMANS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PARASYMPATHOLYTICS;

EID: 0032428543     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050549     Document Type: Article

References (25)

1. Andreasen PB, Ranek L, Statland BE, Tygstrup N (1974) Clearance of antipyrine dependence of quantitative liver function. Eur J Clin Invest 4: 129-134
2. Branch RA (1982) Drugs as indicators of hepatic function. Hepatology 2: 97-105
3. Branch RA, James J, Read AE (1976) A study of factors influencing drug disposition in chronic liver disease, using the model (+)-propranolol. Br J Clin Pharmacol 3: 243-249
4. Dylewicz P, Kirch W, Santos SR, Hutt HJ, Mönig H, Ohnhaus EE (1987) Bioavailability and elimination of nitrendipine in liver disease. Eur J Clin Pharmacol 32: 563-568
5. Eichelbaum M, Somogyi A (1977) Rapid and sensitive method for the determination of antipyrine in biological fluids by high pressure liquid chromatography. J Chromatogr 140: 288-292
6. Haustein KO, Hüller G (1988) On the pharmacokinetics and metabolism of propiverine in men. Eur J Drug Metab Pharmacokinet 13: 81-90
7. Hunter J. Hirst B (1997) Intestinal secretion of drugs. The role of P-glycoprotein and related drug efllux systems in limiting oral drug absorption. Adv Drug Deliv Rev 25: 129-57
8. Kaim AAH, Farker K (1992) Pharmacokinetics and pharmacodynamics of gallopamil in patients with liver cirrhosis (abstract no. 36). Naunyn-Schmiedeberg's Arch Pharmacol 345 [Suppl]: R9
9. Kirch W, Rose I, Demers HG, Leopold G, Pabst J. Ohnhaus EE (1987) Pharmacokinetics of bisoprolol during repeated oral administration to healthy volunteers and patients with kidney or liver disease. Clin Pharmacokinet 13: 110-113
10. Kirch W, Nokhodian A, Halabi A, Weidinger G (1992) Clinical pharmacokinetics of the nifedipine/codergocrine combination in impaired liver and renal function. Eur J Drug Metab Pharmacokinet 17: 33-38
11. Kirch W, Halabi A, Nokhodian A (1993) Disposition and elimination of bunazosin in chronic liver disease and renal insufficiency Eur J Drug Metab Pharmacokinet 18: 309-313
12. Kleinbloesem CH, Van Harten J, Wilson JPH, Danhof M, van Brummelen P, Breimer DD (1986) Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after i. v. and oral administration. Clin Pharmacol Ther 40: 21-28
13. Koytchev R, Alken RG (1994) Pharmacokinetics of propiverine and its metabolites after intravenous and oral administration of propiverine hydrochloride as a single dose in healthy volunteers including determination of absolute bioavailability of Mictonorm. CCDRD. Berlin (unpublished report)
14. Lasseter KC, Shambleu EC, Murdoch AA, Burkholder DE, Krol GJ, Taylor Jr RJ, Vanov SK (1984) Steady-state pharmacokinetics of nitrendipine in hepatic insufficiency. J Cardiovasc Pharmacol 6 [Suppl 7]: 977-981
15. Müller C, Siegmund W, Huupponen R, Kaila T, Franke G, Iisalo E (1993) Kinetics of propiverine as assessed by radioreceptor assay in poor and extensive metabolizers of debrisoquine. Eur J Drug Metab Pharmacokinet 18: 265-272
16. Richter K, Scheithauer S, Thümmler D (1998) High performance liquid chromatography determination of propiverine and its N-oxide metabolite in human serum. J Chromatogr B 708: 325-329
17. Sachs L (1992) Angewandte Statistik. Springer, Berlin Heidelberg New York
18. Shull HJ, Wilkinson GR, Johnson R, Schenker S (1976) Normal disposition of oxazepam in acute viral hepatitis and cirrhosis. Ann Int Med 84: 420-425
19. Siegmund W, Nigussie M, Tilahun K, Aitenfissu H, Franke G, Wengler A (1990) Anticholinergic properties of propiverine and its metabolites. Pharmazie 45: 67-68
20. Somogyi A, Albrecht M, Kliems G, Schäfer K, Eichelbaum M (1981) Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis. Br J Clin Pharmacol 12: 51-60
21. Sotaniemi EA, Pelkonen RO, Arranto AJ, Säkö S, Anttila M (1983) Effect of liver function on β-blocker kinetics. Drugs 25 [Suppl 2]: 113-120
22. Wacher VJ, Wu CY, Benet LZ (1995) Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications of drug delivery and activity in cancer chemotherapy. Mol Carcinogen 13: 129-134
23. ®) beim Menschen. Pharmazie 43: 652-653
24. Wengler A, Siegmund W, Klebingat KJ, Schütz M, Kaliwe E (1989) Metabolismus von Propiverin in adulten und fetalen Humanlebermikrosomen. Z Klin Med 44: 221-224
25. Williams RL, Schary WL, Blaschke TF, Meffin PJ, Melmon KL, Rowland M (1976) Influence of acute viral hepatitis on disposition and pharmacologic effect of warfarin. Clin Pharmacol Ther 20: 90-97